Table 1.
Clinical data of Cleveland Clinic patients who received neoadjuvant chemotherapy with incomplete pathologic response.
| Patient | Age | Tumor Type | Pre-treatment clinical T and N |
ER (% cells immunoreactive) |
PR (% cells immunoreactive) |
HER2 amplification (HER2/CEP 17 ratio) |
Pathologic grade |
Post-treatment pathologic T and N |
Residual Cancer Burden Class |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 41 | Ductal | T3 N1 | 0.9 | 0.7 | absent (1.3) | 2 | pT2 pN1 | RCB-III |
| 2 | 56 | Lobular | T3 N1 | 0.8 | 0.05 | absent (1.3) | 3 | pT2 pN1 | RCB-III |
| 3 | 61 | Ductal | T2 N1 | 0.9 | 0.9 | absent (1.4) | 3 | pT1 pN1 | RCB-III |
| 4 | 68 | Lobular | T2 N0 | 0.7 | 0.7 | absent (1.0) | 1 | pT2 pN1 | RCB-II |
| 5 | 65 | Ductal | T2 N1 | 0.9 | 0.7 | absent (1.4) | 2 | pT2 pN1 | RCB-III |
| 6 | 59 | Ductal | T3 N2 | − (<5%) | − (<5%) | absent (1.0) | 3 | pT3 pN3 | RCB-III |
| 7 | 44 | Ductal | T3 N1 | 0.7 | − (<5%) | absent (1.3) | 1 | pT1 pN1 | RCB-II |
| 8 | 35 | Ductal | T2 N0 | 0.8 | − (<5%) | absent (1.8) | 2 | pT2 pN1 | RCB-III |